Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

November 3rd 2023

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Role of Radiation Continues to Grow in the Treatment of Prostate Cancer

November 3rd 2023

Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.

Strategic Active Surveillance Methods Drive Patient-Focused Prostate Cancer Care

November 3rd 2023

Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.

Genomics Help Drive Active Surveillance Decisions in Low-Risk Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.

State of the Science Summit - Prostate Cancer: Chaired by Alan H. Bryce, MD and Phillip J. Koo, MD

November 3rd 2023

State of the Science Summit - Prostate Cancer: Chaired by Alan H. Bryce, MD and Phillip J. Koo, MD

Dr Spratt on Sequencing Radiation Therapy and Hormone Therapy in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC

October 27th 2023

The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.

Relugolix Wins Approval in Canada for Advanced Prostate Cancer

October 23rd 2023

Health Canada has approved relugolix for the treatment of men with advanced prostate cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Boosts rPFS in Taxane-Naïve mCRPC After Prior AR Inhibitor

October 23rd 2023

Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor.

Niraparib Plus Abiraterone and Prednisone Elicits OS Benefit in BRCA1/2+ mCRPC

October 22nd 2023

The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Enzalutamide Delivers No rPFS or OS Benefits in mCRPC

October 22nd 2023

Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Elicits PSA-PFS Improvement in mCRPC

October 20th 2023

Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

October 19th 2023

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

Data Continue to Support Triplet Therapy With ADT, AR-Targeted Therapy, and Chemotherapy in mHSPC

October 18th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.

Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches for Treatment Selection in Prostate Cancer

October 18th 2023

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.

Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management

October 18th 2023

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

Hurwitz on the Safety Profile of Simultaneous Integrated Boost Plus SBRT in Prostate Cancer

October 13th 2023

Joshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

October 13th 2023

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

State of the Science Summit - Prostate/RCC: Chaired by Marijo Bilusic, MD, PhD

October 11th 2023

State of the Science Summit - Prostate/RCC: Chaired by Marijo Bilusic, MD, PhD